Request Demo

Last update 10 Jan 2026

Oxycodone Hydrochloride

Last update 10 Jan 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Oxycodone hydrochloride (USP), Oxycodone Hydrochloride Hydrate, ATLP-02

+ [32]

Target

Opioid receptors

Action

agonists

Mechanism

Opioid receptors agonists(Opioid receptors agonists)

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

Cancer PainPain

Inactive Indication

Acute PainAnalgesiaChronic Pain+ [2]

Originator Organization

Roxane Laboratories, Inc.

Active Organization

Shionogi Pharma Co., Ltd.SpecGx LLC

Purdue Pharma LP

+ [3]

Inactive Organization

Egalet Ltd.

Keenova Therapeutics Plc

Beijing Mengdi Pharmaceutical Co. Ltd.

+ [4]

License Organization

Protega Pharmaceuticals, LLC.

Inspirion Delivery Sciences LLC

Daiichi Sankyo, Inc.

+ [1]

Drug Highest PhaseApproved

First Approval Date

United States (26 Oct 1998),

Pain

Regulation-

Structure/Sequence

Molecular FormulaC18H22ClNO4

InChIKeyMUZQPDBAOYKNLO-RKXJKUSZSA-N

CAS Registry124-90-3

604

Clinical Trials associated with Oxycodone Hydrochloride

ChiCTR2600115963

/ Not yet recruitingPhase 2IIT

The Effect of Dexmedetomidine Combined with Oxycodone on Postoperative Analgesic Efficacy and Enhanced Recovery After Endoscopic Submucosal Dissection (ESD) of the Esophagus and Stomach

Start Date01 Jan 2026

Sponsor / Collaborator

Nanjing Drum Tower Hospital

ChiCTR2500115160

/ Not yet recruitingNot ApplicableIIT

Application of Hydromorphone Hydrochloride Extended-release Tablets in Cancer Pain Patients with Poor Analgesic Effect of Oxycodone Hydrochloride Sustained-Release Tablets：A Randomized, Single-blind Controlled Study

Start Date01 Jan 2026

Sponsor / Collaborator

Beijing Union Medical College Hospital, Chinese Academy of Medical Sciences

ChiCTR2500114915

/ Not yet recruitingNot ApplicableIIT

Observational study of sustained-release hydromorphone tablets for refractory cancer pain in China

Start Date31 Dec 2025

Sponsor / Collaborator

The Second Affiliated Hospital Zhejiang University

100 Clinical Results associated with Oxycodone Hydrochloride

100 Translational Medicine associated with Oxycodone Hydrochloride

100 Patents (Medical) associated with Oxycodone Hydrochloride

4,212

Literatures (Medical) associated with Oxycodone Hydrochloride

01 Dec 2025·JOURNAL OF HEALTH ECONOMICS

From addiction to aggression: The spillover effects of opioid policies on intimate partner violence

Article

Author: Erten, Bilge ; Zhang, Shuo ; Keskin, Pinar ; Dave, Dhaval

Substance abuse is a major risk factor for intimate partner violence (IPV). We investigate how a key supply-side intervention - the abuse-deterrent reformulation of a widely-diverted opioid, OxyContin - affected IPV. Our results indicate counties with greater baseline rates of prescription opioid usage experienced relatively larger declines in IPV after OxyContin's reformulation. The reformulation reduced IPV only in states with smaller illicit drug markets, while states with larger illicit drug markets experienced increased heroin-involved IPV due to substitution towards illicit opioids. Our results underscore the importance of identifying populations at high risk of substitution to illicit opioids and moderating this risk with evidence-based policies.

02 Nov 2025·BRITISH JOURNAL OF CANCER

Aberrant PJA2-CHRM3 signaling creates a therapeutic vulnerability in gastric tumor

Article

Author: Zhang, Ling ; Gu, Yuan ; Wang, Leihao ; Yin, Jingyi ; Huang, Liyu ; Wang, Xuefei ; Liang, Dongli ; Wang, Zhaoming ; Niu, Yinan ; Zhao, Junjie ; Li, Lingmeng ; Liu, Wenshuai ; Fu, Guoxiang ; Hua, Guoqiang

BACKGROUND:

Vagal innervation plays a pivotal role in gastric tumorigenesis and tumor progression. However, the upstream signaling regulating acetylcholine receptors (AChRs) and its contribution to carcinogenesis remains largely elusive.

METHODS:

We constructed Trp53^-/-; Cdh1^-/- mouse gastric organoids to recapitulate the morphological and functional characteristics of diffuse-type gastric cancer (DGC) for FDA-approved drug (1464 compounds) screening. We investigated the effects of AChR inhibitors in diffuse-type patient-derived organoids (PDOs) by examining IC₅₀ and xenograft tumorigenesis. Mass spectrometry and Co-immunoprecipitation was used to identify the interaction between cholinergic receptor muscarinic 3 (CHRM3) and PJA2. Ubiquitination and degradation assays were used to explore the regulation of CHRM3 by PJA2. 120 human gastric cancer specimens and GEO database were used to explore the clinical relevance of PJA2-CHRM3 signaling.

RESULTS:

mAChR inhibitors were identified as the most effective at suppressing Trp53^-/-; Cdh1^-/- organoids. Consistently, the viability of PDOs with aberrant expression of CHRM3 can be significantly inhibited by oxybutynin hydrochloride (OXY) and nortriptyline hydrochloride (NOR). Mechanistically, the RING E3 ligase PJA2 ubiquitinates and degrades CHRM3, subsequently suppressing downstream TGFβ-pSMAD3 signaling and tumor cell progression. Clinically, low PJA2 expression was correlated with high CHRM3, p-SMAD3 and choline acetyltransferase (ChAT) expression and predicted poor outcomes. Biologically, PJA2 but not its catalytically dead ΔRING mutant could suppress PDOs with aberrant CHRM3 signaling. PJA2 depletion enhanced tumor metastasis of gastric cancer cells, subsequently reversed by OXY and NOR treatment.

CONCLUSIONS:

This previously unknown PJA2-CHRM3 signaling axis provides further understanding of cholinergic innervation as well as identifies a new therapeutic vulnerability in DGC.

01 Oct 2025·PALLIATIVE MEDICINE

Oxycodone/naloxone PR versus oxycodone PR in advanced cancer: A multi-centre randomised trial (ENhANCE trial)

Article

Author: Grobler, Anneke ; Mendis, Ruwani ; Philip, Jennifer ; Le, Brian ; Wong, Aaron K

Background::

Opioid-induced constipation is a common side effect of Oxycodone. Oxycodone/Naloxone Prolonged Release (OXN PR) mitigates opioid-induced constipation in non-cancer pain, however its evidence is limited in people with pain from advanced cancer.

Aims::

To demonstrate analgesic non-inferiority, and superiority in reducing constipation for Oxycodone/Naloxone Prolonged Release (OXN PR) compared to Oxycodone Prolonged Release (Oxy PR).

Design::

Multi-centre open-label randomised controlled trial comparing OXN PR to Oxy PR over 5 weeks. The primary aim was to demonstrate analgesic non-inferiority of OXN PR compared to Oxy PR. The secondary aim was to demonstrate superiority of constipation reduction in the OXN PR arm.

Setting/participants::

Participants with moderate-severe pain (⩾4/10) from advanced cancer were eligible.

Results::

Thirty seven of planned 96 patients were recruited with the study stopping early due to enrolment challenges during the COVID-19 pandemic. Average pain was −1.5 points (95% CI −3.3; 0.4) favouring the OXN PR arm compared to Oxy PR at 5 weeks, meeting analgesic non-inferiority, defined as falling within a one point non-inferiority margin. The OXN PR arm demonstrated less constipation with a significantly lower Bowel Function Index score (−24.87 (95% CI 47.54; 2.21), p = 0.03) compared to Oxy PR. Adverse effect safety profile favoured OXN PR.

Conclusions::

OXN PR is non-inferior to Oxy PR in analgesic effectiveness and superior in reducing constipation. These results indicate OXN PR as the choice of opioid preparation in advanced cancer. Future studies may explore adding naloxone to other slow and immediate release opioid preparations.

Trial registry::

Australian New Zealand Clinical Trials Registry

Trial registration number::

ACTRN12619001282178

URL of trial registry record::

https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=377673&isReview=true

233

News (Medical) associated with Oxycodone Hydrochloride

08 Jan 2026

·www.globenewswire.com

Tris Pharma Announces Acceptance of New Publication Highlighting Promise of Dual NOP-MOP (dual-NMR) Agonists for the Treatment of Moderate-to-Severe Pain

– Preferential MOP agonists such as oxycodone are often required for effective management of moderate to severe pain but come with significant risks of addiction and overdose – – With Dual NMR agonists, NOP and MOP agonism combine to provide analgesia while NOP counters many of the negative effects of MOP receptor agonism – – Dual NOP-MOP agonists have the potential to provide comparable analgesia, but with a substantially lower risk of abuse, addiction, and overdose than preferential MOP agonists such as oxycodone – MONMOUTH JUNCTION, N.J., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company, today announced the acceptance of its peer-reviewed article “The Therapeutic Potential of Dual-NMR (NOP/MOP) Agonism in Pain Management” for publication in Pain and Therapy. Since its discovery in 1995, the nociception / orphanin FQ (NOP) receptor system has been an area of intense research. This paper presents the current state of understanding of the NOP receptor system and its interplay with the μ-opioid (MOP) receptor system. Additionally, the paper discusses the data that has been generated on a new class of dual NOP/MOP (dual-NMR) analgesics which has the promise of providing potent analgesia with a significantly lower risk of negative side effects associated with preferential MOP agonists such as oxycodone or morphine. Key findings from the publication include: Preferential MOP agonists, like morphine and oxycodone, are often the only effective treatments for moderate-to-severe pain, yet carry significant risks including physical dependence, tolerance, addiction, and respiratory depressionDespite sharing partial structural homology to opioid receptors, the NOP receptor has a distinct pharmacological profile: its activation produces analgesia while minimizing several side effects associated with MOP-only activationDual-NMR receptor agonists, which simultaneously activate both NOP and MOP receptors, have been designed to combine the pain-relieving benefits of both NOP and MOP activation, while mitigating many of the negative effects of preferential MOP agonism, offering a more balanced approach to pain managementStudies show that dual-NMR agonists provide strong analgesia across various pain types with a lower risk of physical dependence, tolerance, addiction, and respiratory depression, highlighting them as a promising new class that may provide effective pain management with a more balanced safety profile “Since its discovery 30 years ago, our understanding of the nociceptin system has grown,” said Dr. Roberto Ciccocioppo, PhD, Professor of Pharmacology at the University of Camerino and an author of the paper. “NOP receptor stimulation was first seen to provide analgesia, then discovered to counter many of the effects of MOP receptor stimulation, and now many studies across multiple compounds have shown that coactivation of NOP and MOP can provide strong analgesia with lower risks of serious side effects than MOP receptor stimulation alone. As a result, I believe dual-NMR agonists represent an important new breakthrough in pain management.” Details of the Publication Title: The Therapeutic Potential of Dual-NMR (NOP/MOP) Agonism in Pain ManagementAuthors: Roberto Ciccocioppo, PhD, University of Camerino; Jeffrey Gudin, MD, University of Miami Miller School of Medicine; Charles Argoff, M.D., Albany Medical College; Ema Offidani, Ph.D., Tris Pharma; James C. Hackworth, Ph.D., Tris Pharma; David Fam, Pharm.D., Tris Pharma; Jim Potenziano, Ph.D., Tris PharmaJournal: Pain and Therapy Tris Pharma commissioned this research in support of its work developing cebranopadol, a first-in-class investigational dual-NMR agonist. About Acute PainAcute pain affects millions of patients each year and is caused by injury, surgery, illness, trauma, burns or painful medical procedures, which can last up to three months, and typically resolves once the underlying cause is treated or healed. Moderate-to-severe acute pain can often only be effectively treated with opioid analgesics such as oxycodone, especially following joint replacements and other orthopedic procedures, invasive surgeries, and major traumas and burns. About Cebranopadol Cebranopadol is a first-in-class investigational therapy that targets two key receptors, the nociceptin/orphanin FQ peptide (NOP) and µ-opioid peptide (MOP) receptors (a dual-NMR agonist), for the treatment of moderate-to-severe pain, as well as opioid use disorder (OUD). These receptors are partially homologous to each other, and they play both complementary and distinct roles to modulate pain biology pathways. Studied in over 33 clinical trials in more than 2,200 subjects, cebranopadol’s profile has been well characterized in pain management studies. It has demonstrated positive clinical results in acute pain, chronic pain and diabetic neuropathic pain with a favorable safety profile. The FDA granted Fast Track Designation to cebranopadol for chronic low back pain, and if approved, it could become the first dual-NMR pain-relief therapy with the potential to provide efficacy equivalent to selective MOP agonists such as oxycodone with less risk of misuse or physical dependence, addiction or overdose. Cebranopadol’s novel mechanism of action has potential in treating patients with substance use disorders (SUDs). Tris plans to continue to evaluate cebranopadol’s potential to help patients break the cycle of opioid addiction. The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), has awarded Tris a five-year grant of up to $16.6 million to study cebranopadol’s potential to treat OUDs and SUDs. About Tris Pharma Tris Pharma is a privately held, innovation-driven biopharmaceutical company that is applying its drug development capabilities and proprietary technologies to transform the treatment of ADHD, pain, addiction and disorders of the central nervous system. Tris markets a portfolio of best-in-class ADHD products and is developing a promising pipeline of differentiated near-term drug candidates. More information is available at www.trispharma.com and on LinkedIn @TrisPharma. Media Contact Jonathan PappasLifeSci Communicationjpappas@lifescicomms.com Company Contact Cheryl PatnickTris Pharma, Inc.cpatnick@trispharma.com

Fast TrackClinical Result

06 Jan 2026

·www.sciencedaily.com

Scientists find a safer way for opioids to relieve pain

Researchers at USF Health have discovered a new way opioid receptors can work that may lead to safer pain medications. Their findings show that certain experimental compounds can amplify pain relief without intensifying dangerous side effects like suppressed breathing. This research offers a fresh blueprint for designing opioids that last longer, work better, and pose fewer risks. It also opens doors to safer treatments for other brain disorders.Scientists at USF Health are making major progress in understanding how new opioid compounds interact with the body to relieve pain. Their work is raising optimism that future pain medications could deliver relief without the life-threatening side effects associated with today's opioids. Their latest findings were published December 17 in Nature under the title "GTP release-selective agonists prolong opioid analgesic efficacy." A companion study, "Characterization of the GTPγS release function of a G protein-coupled receptor," appeared the same day in Nature Communications. "Our overarching research aims to understand how opioids work so that we can ultimately provide safer options for chronic pain and develop therapies for opioid use disorders," said senior author Laura M. Bohn, PhD, senior associate dean for Basic and Translational Research and professor of Molecular Pharmacology and Physiology at the USF Health Morsani College of Medicine. How Opioids Relieve Pain and Cause Harm The studies focus on a group of experimental pain-relieving compounds that act on mu opioid receptors. These receptors are proteins found on nerve cells that reduce pain signals when activated by opioids such as morphine. However, activating these receptors also triggers serious side effects. Drugs like morphine can slow breathing, a dangerous effect that contributes to overdose deaths. Dr. Bohn and her team are working to develop compounds that ease pain without causing these harmful reactions. Their research reveals previously unknown ways opioid receptors behave when different drugs bind to them. New Insights Into Receptor Behavior Although the research is not expected to produce a new medication right away, it significantly improves scientific understanding of how receptors function, said Edward Stahl, PhD, assistant professor of Molecular Pharmacology and Physiology at the Morsani College of Medicine and a corresponding author on the study, which received funding from the National Institutes of Health. "Our manuscripts describe a unique way that drugs can control receptors," Dr. Stahl said. "Fundamentally, knowing more about how receptors work is the first step in understanding how to drug them and how to drug them safer. If this research is further validated, it would add to our textbook knowledge of how receptors function and, more importantly, to our ability to treat human health and disease." Reversing the Opioid Signal When opioids bind to a receptor, they trigger a sequence of events inside the cell that leads to pain relief and side effects. Long-term use of drugs such as morphine, oxycodone, and fentanyl often results in tolerance and dangerous breathing suppression. The researchers discovered that the earliest step in this signaling process can move in reverse. Some compounds appear to favor this backward reaction instead of pushing the process forward. "We've found that the first step of the chain reaction is reversible, and that some drugs can favor a reverse reaction over the forward reaction," Dr. Bohn said. "We've studied two new chemicals that strongly favor the reverse cycle and, when administered at non-effective doses, can enhance morphine and fentanyl-induced pain relief while not enhancing the respiratory suppression effects." Promising Frameworks, Not Final Drugs The newly studied molecules are not considered drug candidates. At higher doses, they still suppress breathing and have not undergone testing for toxicity or other opioid-related side effects. Even so, they provide valuable guidance for future drug design. "They do provide the framework for building new drugs," Dr. Bohn said. Building on Earlier Breakthroughs Dr. Bohn's laboratory previously identified a compound known as SR-17018. Unlike traditional opioids, SR-17018 does not cause breathing suppression or tolerance. It activates the same opioid receptor targeted by morphine, oxycodone, and fentanyl, but it attaches in a different way that leaves the receptor available for the body's own natural pain-relieving chemicals. While SR-17018 also favors the reverse signaling direction, researchers believe other features contribute to its improved safety profile. "For this reason," Dr. Bohn said, "we will be using our new findings to improve upon SR-17018." Broader Implications Beyond Pain Relief The research could influence drug development beyond opioids. Other receptors, including the serotonin 1A receptor, may also be activated in a reverse direction. According to Dr. Bohn, "this is an important drug target in neuropsychiatric disorders, including depression and psychosis." Context Within the Opioid Crisis These discoveries arrive amid an ongoing public health emergency linked to opioid misuse. Data show that opioids were involved in 68 percent of overdose deaths in 2024, with fentanyl and other synthetic opioids accounting for 88 percent of those fatalities. Dr. Bohn, an internationally recognized expert in molecular pharmacology and neurobiology, recently joined USF Health. She is widely known for her groundbreaking research on G protein-coupled receptors (GPCRs), the largest class of drug targets in the human body. Her lab has played a key role in revealing how selective signaling at opioid receptors can reduce pain without causing breathing suppression or tolerance. These findings deepen scientific understanding of opioid biology and move researchers closer to developing safer, non-addictive pain treatments.

20 Nov 2025

·ir.ensysce.com

Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach

~ FDA Response Streamlines Path to Commercial Production of PF614~ SAN DIEGO, CA / ACCESS Newswire / November 20, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system therapeutics designed to minimize abuse and overdose risk, today announced that the Food and Drug Administration (FDA or Agency) provided Written Responses to a meeting request. Ensysce had requested guidance on its approach to the manufacture of PF614, wanting to understand the appropriateness of regulatory starting materials (RSMs) and specifications for PF614 drug substance and the RSMs. In its written responses, the Agency agreed with all of Ensysce's proposed plans. These responses provide Ensysce with a direct path to commercial production of PF614, which is currently being initiated with its manufacturing partner, Purisys, LLC, a subsidiary of Noramco, LLC. Dr. Jeff Millard, Chief Operating Officer of Ensysce who lead the CMC effort stated "We are extremely pleased with the FDA's feedback, which validates our approach and enables us to accelerate PF614's path to market. This milestone brings us closer to providing safer pain relief options for patients in need." "The feedback from the FDA now provides us with a clear path to scaling our manufacture of PF614 for its commercial production," said Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce. "PF614 is our TAAP™ oxycodone analogue and the leading product in our Next Generation Analgesic pipeline of TAAP™ and MPAR® products. We are exceptionally pleased that our meeting package was so well received and that we are aligned with the FDA requirements for producing this novel therapeutic that is designed to alleviate moderate to severe pain while providing what we believe are safer qualities for the general public who require this level of pain relief." About Ensysce Biosciences Ensysce Biosciences is a clinical-stage company with a goal of disrupting the analgesic landscape by introducing a new class of highly novel opioids for the treatment of severe pain. Leveraging its Trypsin-Activated Abuse Protection (TAAP™) and Multi-Pill Abuse Resistance (MPAR®) platforms, the Company is developing unique, tamper-proof treatment options for pain that minimize the risk of both drug abuse and overdose. Ensysce's products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse. For more information, please visit www.ensysce.com. Forward-Looking Statements Statements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as "may," "intends," "can," "might," "will," "expect," "plan," "possible," "believe" and other similar expressions are intended to identify forward-looking statements. The product candidates discussed are in clinic and not approved and there can be no assurance that the clinical programs will be successful in demonstrating safety and/or efficacy, that Ensysce will not encounter problems or delays in clinical development, or that any product candidate will ever receive regulatory approval or be successfully commercialized. All forward-looking statements are based on estimates and assumptions by Ensysce's management that, although Ensysce believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Ensysce expected. In addition, Ensysce's business is subject to additional risks and uncertainties, including among others, possible NASDAQ delisting, the initiation and conduct of preclinical studies and clinical trials; the timing and availability of data from preclinical studies and clinical trials; expectations for regulatory submissions and approvals; potential safety concerns related to, or efficacy of, Ensysce's product candidates; the availability or commercial potential of product candidates; continuation of government funding; the ability of Ensysce to fund its continued operations, including its planned clinical trials; the dilutive effect of stock issuances from our fundraising; and Ensysce's and its partners' ability to perform under their license, collaboration and manufacturing arrangements. These statements are also subject to a number of material risks and uncertainties that are described in Ensysce's most recent quarterly report on Form 10-Q and current reports on Form 8-K, available free of charge at the SEC's website at www.sec.gov. Any forward-looking statement speaks only as of the date on which it was made. Ensysce undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required under applicable law. Ensysce Biosciences Company Contact: Lynn Kirkpatrick, Ph.D. Chief Executive Officer (858) 263-4196 Ensysce Biosciences Investor Relations Contact: Shannon Devine MZ North America Main: 203-741-8811 ENSC@mzgroup.us SOURCE: Ensysce Biosciences Inc. Released November 20, 2025

100 Deals associated with Oxycodone Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D00847	Oxycodone Hydrochloride	N02AA05	DBSALT000277

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Cancer Pain	Japan	Shionogi Pharma Co., Ltd.	01 May 2012
Acute Pain	China	Bard Pharmaceuticals Ltd.	21 Jan 2004
Chronic Pain	China	Bard Pharmaceuticals Ltd.	21 Jan 2004
Pain	United States	Roxane Laboratories, Inc.	26 Oct 1998

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Low Back Pain	Phase 3	United States	Egalet Ltd.	01 Mar 2016
Osteoarthritis, Spine	Phase 3	United States	Purdue Pharma LP	01 Apr 2004
Analgesia	Phase 1	United States	Purdue Pharma LP	01 Jul 2010
Analgesia	Phase 1	Australia	Purdue Pharma LP	01 Jul 2010
Analgesia	Phase 1	Finland	Purdue Pharma LP	01 Jul 2010
Analgesia	Phase 1	New Zealand	Purdue Pharma LP	01 Jul 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05974501 (CTgov)	Phase 4	complications of arthroplasty \| Osteoarthritis, Knee \| Pain, Postoperative	84	Lyrica+Ropivacaine+Acetaminophen+Oxycodone+Dexamethasone+Celebrex+Meloxicam (Preoperative Adductor Canal Block Group)	kswubzhebq(odafildchd) = fhjzzakqlm ifsjhexwjz (jhfekstubt, lrnyyaffzw - cmctduydfs) View more	-	12 Feb 2025
				Lyrica+Ropivacaine+Acetaminophen+Oxycodone+Dexamethasone+Celebrex+Meloxicam (Postoperative Adductor Canal Block Group)	kswubzhebq(odafildchd) = zkijxizjle ifsjhexwjz (jhfekstubt, atinlurhdf - nnlaolvtys) View more
NCT01458015 (CTgov)	Phase 4	Neuralgia	3	oxycodone+tapentadol (Oxycodone)	udxideyofe(ougwivybpr) = nvgsprvyfc bhqpaddyvd (czwglhhjab, hhegxtetus - mtnkrsvdpe) View more	-	17 Dec 2024
				oxycodone+tapentadol (Tapentadol)	udxideyofe(ougwivybpr) = ihxbkgalay bhqpaddyvd (czwglhhjab, zbeavmpxxu - priekupbbm) View more
NCT03859024 (CTgov)	Phase 4	Urethral Stricture \| Pain, Postoperative	48	Acetaminophen+Oxycodone+Ibuprofen 800 mg (Standard Protocol)	vxjatgmkag(wmohtburbz) = vgmpyzywkx wmyobsthjv (ielpdautys, lrhzvxafkb - fkhwupveku) View more	-	19 Sep 2024
				Acetaminophen+Oxycodone+Dexamethasone+Ibuprofen 800 mg+Bupivacaine+celebrex+Gabapentin (Enhanced Recovery Protocol)	vxjatgmkag(wmohtburbz) = pueioclxhh wmyobsthjv (ielpdautys, rfnjccuole - xevzeflinz) View more
NCT04791761 (CTgov)	Phase 1/2	Pain, Postoperative	73	Opioid disposal education+Acetaminophen+Oxycodone+Ibuprofen (Opioid Pain Control)	dmcogytmnx(regpjbzwtw) = bwnwzzdsek yomlqccrqg (voqquzwyog, vjqrjxdgup - gatiozxjuy) View more	-	16 Aug 2024
				Acetaminophen+Ibuprofen (Non-opioid Pain Control)	dmcogytmnx(regpjbzwtw) = yvvfgdqefx yomlqccrqg (voqquzwyog, rmmpshuqds - okysvdxbyq) View more
NCT04015908 (CTgov)	Phase 4	-	100	Pregabalin+Acetaminophen+Oxycodone+celecoxib (Multi-modal)	uxvnjmdjlr(ftthqquuou) = nbrypajeht lhjitxkhgt (prbvzzkslb, gjchvmfdmh - bvqivcmlda) View more	-	08 Jul 2024
				Percocet (Control)	uxvnjmdjlr(ftthqquuou) = loberkzpyz lhjitxkhgt (prbvzzkslb, vbxicczves - czjkaavznf) View more
NCT03612713 (CTgov)	Early Phase 1	Drug abuse	20	Oxycodone (Oxycodone Run)	kqmoltibqv(kidosolkyo) = spcydmyccu ybtcicdbhz (kavmvnlaxq, 1.37) View more	-	08 Mar 2024
				placebo (Placebo Run)	kqmoltibqv(kidosolkyo) = fmisfgcobi ybtcicdbhz (kavmvnlaxq, 2.46) View more
NCT04122443 (CTgov)	Phase 4	Musculoskeletal Pain	393	Acetaminophen+Ibuprofen (Ibuprofen and Then Acetaminophen (Stage 2))	zbucgdvssf(dfdzfguynz) = swskpfyogv jqojynlxdx (jyjvmchttd, 2.4) View more	-	28 Feb 2024
				Acetaminophen+Oxycodone+Ibuprofen (Ibuprofen and Then Oxycodone/Acetaminophen (Stage 2))	zbucgdvssf(dfdzfguynz) = bkwgfmdwax jqojynlxdx (jyjvmchttd, 2.6) View more
NCT04285853 (CTgov)	Phase 4	Anterior Cruciate Ligament Injuries	98	Oxycodone (Oxycodone Arm)	oryogvbkoi(esbowtptld) = zvoubdpycq qhvfppybhp (xlandhdrej, nyebtdixgj - usmvvbklcs) View more	-	11 Oct 2023
				Placebo oral tablet (Placebo Arm)	oryogvbkoi(esbowtptld) = fqltydlffk qhvfppybhp (xlandhdrej, staeqzjdis - eydzvpwqql) View more
NCT04149964 (CTgov)	Phase 4	Fistula \| Pain, Postoperative	65	Acetaminophen/Hydrocodone 325 mg/7.5 mg oral tablet+Acetaminophen 325 mg Oral Tablet (Standard of Care Arm)	ifgbyhcaew(zfxcfbblsi) = mrlnfhzdym golvftiuxj (vmbvaggskq, jrhbahxibw - vcrvvmgtri) View more	-	31 Aug 2023
				Acetaminophen 650 mg Oral Tablet+OxyCODONE 5 mg Oral Tablet (Study Arm)	ifgbyhcaew(zfxcfbblsi) = iwcxyeytoy golvftiuxj (vmbvaggskq, hbowzlfzgc - pvysldqipp) View more
NCT05319756 (CTgov)	Phase 4	-	54	oxycodone HCl 20 mg (Oxycodone HCl 20 mg Single Dose)	zxuukytqey(itnpcndhkt) = qfvmzmowog mduljfydut (trfvowrijc, 3.156) View more	-	14 Aug 2023
				gabapentin 600 mg (Gabapentin 600 mg Single Dose)	zxuukytqey(itnpcndhkt) = grimykodvf mduljfydut (trfvowrijc, 3.142) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis